The US Food and Drug Administration this week announced reforms to its Office of Oncology Drug Products that should improve the group's ability to review marketing applications for pharmacogenomically guided cancer drugs, according to an agency spokesperson.

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.